Compare Amphastar Pharmaceuticals Inc (AMPH) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Banco Bilbao Vizcaya Argentaria SA trades at $25.8 (market cap $141.88B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 171.8× Amphastar Pharmaceuticals Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BBVA | |
|---|---|---|
Market Cap | $826.08M | $141.88B |
Sector | Health | Financials |
52-Week High | $30.81 | $26.14 |
52-Week Low | $16.87 | $14.73 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
BBVA trades at $25.69, up 1.3% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with 26.51% net income margin and 18.67% ROE, though recent legal challenges from Spain's High Court regarding a spying case present headwinds. Earnings have mostly beaten expectations, with Q1 2026 EPS of $0.60 exceeding the $0.57 forecast.
The stock offers value with a P/E of 12.39 and receives strong analyst support (53.85% buy ratings), but investors should weigh regulatory risks and volatile cash flows against the positive earnings trajectory and technical momentum for medium-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
